3/6
08:55 am
regn
Regeneron Pharmaceuticals (REGN) is now covered by Barclays PLC. They set an "overweight" rating and a $923.00 price target on the stock.
Low
Report
Regeneron Pharmaceuticals (REGN) is now covered by Barclays PLC. They set an "overweight" rating and a $923.00 price target on the stock.
3/6
08:45 am
regn
Rating for REGN
Low
Report
Rating for REGN
3/6
08:45 am
regn
Rating for REGN
Low
Report
Rating for REGN
3/6
05:08 am
regn
Regeneron initiated with an Overweight at Barclays
Low
Report
Regeneron initiated with an Overweight at Barclays
3/6
05:08 am
regn
Regeneron initiated with an Overweight at Barclays
Low
Report
Regeneron initiated with an Overweight at Barclays
3/2
11:51 am
regn
Rating for REGN
Low
Report
Rating for REGN
3/2
11:51 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/9
09:48 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/9
09:48 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
12:58 pm
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
12:47 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $865.00 price target on the stock, up previously from $750.00.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $865.00 price target on the stock, up previously from $750.00.
2/2
12:12 pm
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
12:12 pm
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
11:36 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
11:36 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
10:33 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
10:33 am
regn
Rating for REGN
Low
Report
Rating for REGN
2/2
10:23 am
regn
Rating for REGN
Low
Report
Rating for REGN
1/22
10:32 am
regn
Rating for REGN
Low
Report
Rating for REGN
1/7
08:02 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "buy" rating. They now have a $860.00 price target on the stock, up previously from $627.00.
Medium
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "buy" rating. They now have a $860.00 price target on the stock, up previously from $627.00.